In the study cohort, 23.2% of patients for whom receptor status was available for both the primary tumor and the metastasis showed ER conversion (McNemar’s test p = 0.026), 33.7% had PR conversion (McNemar’s test p < 0.001), and 10.1% had HER2 conversion (McNemar’s test p = 1.000) (supplementary table 1). Here, ERBB2 is linked to neoplasm.